The Business Research Company’s report on the Proteasome Inhibitors Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the key drivers behind the proteasome inhibitors market’s growth in recent years?
The increasing prevalence of pancreatic cancer is expected to propel the growth of the proteasome inhibitors market going forward. Pancreatic cancer is a type of cancer that develops in the cells of the pancreas, an organ located in the abdomen behind the stomach. Proteasome inhibitors are primarily used to treat pancreatic cancer, where proteasome plays a critical role in promoting cell survival and growth by degrading proteins that regulate cell cycle progression and cell death. It disrupts cancer cell survival and inhibits tumor growth and metastasis. For instance, in January 2024, according to the reports by the American Cancer Society, a US-based health organization, an estimated 64,050 adults in the US were diagnosed with pancreatic cancer by 2023, and 50,550 people died of pancreatic cancer. Furthermore, the number increased to 66,440, with the number of deaths reaching 51,750. Therefore, the increasing prevalence of pancreatic cancer is driving the growth of the proteasome inhibitors market.,
Access Your Free Sample of the Global Proteasome Inhibitors Market Report – Get Insights Now!
Proteasome Inhibitors Market Report 2025, Statistics, Size, Forecast Sample
How does the future projection of the proteasome inhibitors market size compare to its historical growth?
The proteasome inhibitors market size has grown strongly in recent years. It will grow from $2.01 billion in 2024 to $2.19 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to scientific breakthroughs, clinical research and trials, FDA approvals, rising cancer cases, advancements in drug delivery
The proteasome inhibitors market size is expected to see strong growth in the next few years. It will grow to $3.2 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to precision medicine approaches, next-generation inhibitors, healthcare infrastructure growth, targeted therapies combination, emerging markets adoption. Major trends in the forecast period include immunotherapy combinations, selective proteasome inhibition, longer half-life inhibitors, oral formulations, resistant cancer variant treatments.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
Proteasome Inhibitors Market Report 2025, Statistics, Size, Forecast Customise
Which key players are shaping the future of the proteasome inhibitors market?
Major companies operating in the proteasome inhibitors market include Pfizer Inc., Johnson And Johnson, AbbVie, Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Fresenius Kabi AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Baxter International Inc., Sigma-Aldrich, Zydus Pharmaceuticals, Onyx Pharmaceuticals Inc., Tocris Bioscience, Accuitis Inc., TG Therapeuticsn Inc., QLi5 Therapeutics GmbH, Progenra Inc., Nurix Inc., Cephalon Inc., Cleave Therapeutics, Lifesensors Inc., MimiVax LLC, Apotex Inc.
What trends will propel the growth and evolution of the proteasome inhibitors market?
Increases in investments are a key trend gaining popularity in the proteasome inhibitors market. Major companies operating in the proteasome inhibitors market are investing in developing and commercializing proteasome inhibitors, which can play a significant role in advancing research and bringing new treatments to the market. For instance, in September 2022, QLi5 Therapeutics GmbH, a Germany-based developer of new-class proteasome inhibitors, received $10.96 million (EUR 10 million) of investments from SV Investment, a South Korea-based venture capital firm, and KHAN Technology Transfer Fund I, a Germany-based venture capital firm, as well as Atinum Investment Co., Ltd. and Daol Investment & Securities Co., Ltd., South Korea-based venture capital firms. This investment aims to develop novel proteasome inhibitors for treating cancer and inflammatory and autoimmune disorders. With the help of this funding, QLi5’s pipeline of very distinct proteasome inhibitors will be advanced to the beginning of clinical studies addressing multiple indications.
Which regions are expected to become dominant players in the proteasome inhibitors market?
North America was the largest region in the proteasome inhibitors market in 2024. The regions covered in the proteasome inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/proteasome-inhibitors-global-market-report
What are the emerging key segments in the proteasome inhibitors market, and how are they evolving?
The proteasome inhibitors market covered in this report is segmented –
1) By Product: Velcade, Kyprolis, Ninlaro, Other Products
2) By Drugs: Bortezomib, Carfilzomib, Ixazomib
3) By Indication: Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-User: Hospital, Specialty Clinics, Other End-Users
Subsegments:
1) By Velcade: Injectable Velcade (Bortezomib), Oral Formulations
2) By Kyprolis: Injectable Kyprolis (Carfilzomib), Combination Therapies With Kyprolis
3) By Ninlaro: Oral Ninlaro (Ixazomib), Combination Therapies With Ninlaro
4) By Other Products: Investigational Proteasome Inhibitors, Combination Products
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
Proteasome Inhibitors Market Report 2025, Statistics, Size, Forecast
What defines the structure and scope of the proteasome inhibitors market?
Proteasome inhibitors refer to a class of drugs that interfere with the activity of proteasomes, which are cellular complexes responsible for degrading proteins in a controlled manner. Proteasome inhibitors are primarily used to treat certain types of cancer, particularly multiple myeloma, and some forms of lymphoma, demonstrating significant efficacy in targeting cancer cells and inducing cell death.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
